The new Gyrolab AAV9 Titer Kit enables researchers to improve productivity and is based on a highly selective AAV9 affinity ligand developed with the Thermo Scientific CaptureSelect technology by Thermo Fisher Scientific.
These ligands are also the basis of POROS CaptureSelect AAV9 Affinity Resin, which is frequently used to purify AAV9 viral vectors.
The new kit adds to the company's existing range of ready-to-use kits, increasing the company's offering for analytical characterization during manufacturing and purification of cell and gene therapies and complementing the Gyrolab AAVX Titer Kit, and the recently launched HEK 293 HCP Solution for Gyrolab (with reagents ordered from Cygnus Technologies).
The AAV9 serotype is attractive as a gene delivery vector owing to its ability to cross the blood-brain barrier and target the central nervous system with high efficiency.
With the industry's focus on faster bench to bedside processes, the new kit supports improved development time and streamlined process transfer due to the standardized reagents and validated methods of the Gyrolab platform, the company said.
Gyros Protein Technologies said the AAV9 Titer Kit provides fast results, enabling 96 data points to be generated in 80 minutes, an improved assay working range compared to ELISA methods, and the ability to handle small sample volumes (10x less compared to an ELISA), helping to reduce development timelines of novel biotherapeutics, including cell and gene therapies.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference